Aim: The severity of COVID-19 has raised a great public health concern evoking an urgency for developing multitargeted therapeutics. Phlomis species was ethno-pharmacologically practiced for respiratory ailments. Materials & methods: An array of 15 phytoligands previously isolated from Phlomis aurea were subjected to molecular docking to explore their potential SARS-CoV-Spike-angiotensin-converting enzyme 2 complex inhibition, that is essential for virus entry to host cell. Results: Acteoside ( 11 ) showed the most potent in silico inhibition with an additional merit, over hesperidin ( 16 ), of not binding to angiotensin-converting enzyme 2 with well proven in vivo pulmonary protective role in acute lung injury, followed by chrysoeriol-7- O -β-glucopyranoside ( 12 ) and luteolin-7- O -β-glucopyranoside ( 14 ). Conclusion: Phytoligands ( 11 , 12 and 14 ) were posed as promising candidates with potential prophylactic action against COVID-19. These phytoligands were prioritized for further biological experimentation because of their acceptable predicted ADME and drug-likeness parameters. Moreover, they could aid in developing multitargeted strategy for better management of COVID-19 using phytomedicines. Graphical abstract
【저자키워드】 SARS-CoV-2, ACE2, molecular docking, Spike protein,